Healthy individuals levodopa, respiration
Conditions
Interventions
Administer a drip infusion by mixing 50 mg of Dopaston (in 20 mL) with 80 mL of normal saline.
levodopa
Sponsors
Tsunemi Taiji
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy individuals aged 40 to 80 years old (Healthy individuals are defined as those who do not have neurological or respiratory disorders and whose daily activities are not impaired). 2. Participants must be able to provide informed consent, and the acquisition of written consent must be possible based on the individual's free will. 3. Individuals who, after considering the selection and exclusion criteria, have been deemed eligible to participate in this study by the principal investigator (or participating physician).
Exclusion criteria
Exclusion criteria: 1. Those with neurological symptoms including subjective parkinsonism (tremor, akinesia, postural instability). 2. Individuals with a resting room air percutaneous oxygen saturation of 94% or less. 3. Those who experience respiratory distress at rest. 4. Individuals who have been indicated by blood tests conducted within the past year to have AST levels above 45 U/L, creatinine levels above 1.2 mg/dL for men, 1.0 mg/dL for women, and HbA1c levels above 6.5%. 5. Patients with a history of or current gastric or duodenal ulcers. 6. Those with severe cardiovascular or pulmonary diseases, bronchial asthma, or endocrine disorders. 7. Individuals with psychiatric symptoms such as suicidal tendencies. 8. Those with symptoms of closed-angle glaucoma. 9. Individuals with a history of hypersensitivity to the components of this drug. 10. Those planning pregnancy (both men and women). 11. Individuals who are pregnant or suspected to be pregnant. 12. Patients using reserpine preparations, antihypertensive drugs, antipsychotic drugs, general anesthetics, pyridoxine, antiparkinsonian drugs, NMDA receptor antagonists, papaverine hydrochloride, iron preparations, or isoniazid. 13. Individuals and their families who are affiliated with the Department of Neurology at Juntendo University Hospital. 14. Others deemed unsuitable as study subjects by the principal investigator (or co-investigator).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in P0.1 from before to after administration of levodopa preparation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Ventilatory response Tidal volume Respiratory rate | — |
Contacts
Public ContactTaiji Tsunemi
Juntendo University Hospital
Outcome results
None listed